SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (10029)9/30/2015 2:34:03 PM
From: scaram(o)uche  Read Replies (3) | Respond to of 12215
 
All of the bulls are constantly pointing at the low tox, relative to duvelisib and idelalisib. Is there ANY demonstration for off-target tox mediated by idelalisib, or is the "dilution" theory that Chimera Research was floating, maybe a year ago, still a possible explanation?

You've seen this?

ncbi.nlm.nih.gov



To: tuck who wrote (10029)11/2/2015 2:22:33 PM
From: tuck  Read Replies (1) | Respond to of 12215
 
" Thinking of letting about a month go by before further buying, on the theory that seasonality will be better by then."

Well, that didn't work. Instead of tanking, the market rallied earlier than expected. It looks as though it needs another breather, IMO, but it might be shallow. Raised a bit of cash today, by selling TRIL for a decent trading profit, and a solar play that worked even better.

Looking at XNCR.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News